<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928681</url>
  </required_header>
  <id_info>
    <org_study_id>A7281001</org_study_id>
    <nct_id>NCT00928681</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis</brief_title>
  <official_title>A Randomized, Double-Blind (Sponsor Open), Placebo Controlled, Dose Escalating, Parallel Group, Multi-Centre Study To Investigate The Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous/Sub-Cutaneous Doses Of PF-00547659 In Patients With Active Ulcerative Colitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      study to investigate the safety and efficacy properties of PF-00547659 in patients with
      active ulcerative colitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and toleration</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endoscopic score changes as calculated using section 3 of the Mayo Score</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity score changes as calculated using the Mayo Score</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of PF-00547659</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal concentrations of calprotectin</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of CRP</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>0.03 mg/kg or placebo iv</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mg/kg or placebo iv</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg/kg or placebo iv</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg/kg or placebo iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg/kg or placebo sc</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg or placebo iv</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg/kg or placebo sc</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mg/kg or placebo iv (multiple dose)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg/kg or placebo iv (multiple dose)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg/kg or placebo iv</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mg/kg or placebo sc</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg/kg or placebo sc (multiple dose)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single dose-group A</intervention_name>
    <description>PF-00547659, single iv dose</description>
    <arm_group_label>0.03 mg/kg or placebo iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single dose-group A</intervention_name>
    <description>PF-00547659, single iv dose</description>
    <arm_group_label>0.1 mg/kg or placebo iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple dose- Group B</intervention_name>
    <description>PF-00547659, multiple dose</description>
    <arm_group_label>0.1 mg/kg or placebo iv (multiple dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single dose-group A</intervention_name>
    <description>PF-00547659, single iv dose</description>
    <arm_group_label>0.3 mg/kg or placebo iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple dose- Group B</intervention_name>
    <description>PF-00547659, multiple dose</description>
    <arm_group_label>0.3 mg/kg or placebo iv (multiple dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single dose-group A</intervention_name>
    <description>PF-00547659, single dose</description>
    <arm_group_label>1.0 mg/kg or placebo iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single dose-group A</intervention_name>
    <description>PF-00547659, single dose</description>
    <arm_group_label>3.0 mg/kg or placebo sc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single dose-group A</intervention_name>
    <description>PF-00547659, single dose</description>
    <arm_group_label>10 mg/kg or placebo iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single dose-group A</intervention_name>
    <description>PF-00547659, single dose</description>
    <arm_group_label>0.3 mg/kg or placebo sc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple dose-Group B</intervention_name>
    <description>PF-00547659, multiple dose</description>
    <arm_group_label>0.3 mg/kg or placebo sc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple dose- Group B</intervention_name>
    <description>PF-00547659, multiple dose</description>
    <arm_group_label>0.1 mg/kg or placebo iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple dose- Group B</intervention_name>
    <description>PF-00547659, multiple dose</description>
    <arm_group_label>0.3 mg/kg or placebo iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple dose- Group B</intervention_name>
    <description>PF-00547659, multiple dose</description>
    <arm_group_label>3.0 mg/kg or placebo iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple dose- Group B</intervention_name>
    <description>PF-00547659, multiple dose</description>
    <arm_group_label>0.1 mg/kg or placebo sc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple dose-Group B</intervention_name>
    <description>PF-00547659, multiple dose</description>
    <arm_group_label>0.3 mg/kg or placebo sc (multiple dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A positive histological diagnosis of UC ≥3 months prior to entry into the study. If a
             histological diagnosis is not available but all signs and symptoms suggest UC, the
             subject's eligibility should be discussed with Pfizer.

          -  Active UC as defined by a score of ≥6 on the Mayo score.

          -  An endoscopic (by flexible sigmoidoscopy) sub-score of ≥2 on the Mayo score determined
             within 7 days of first dosing.

        Exclusion Criteria:

          -  Subjects with UC, which is confined to a proctitis on a flexible sigmoidoscopy.

          -  Subjects who have had surgery as a treatment for UC or are likely to require surgery
             within the duration of the study.

          -  Subjects displaying clinical signs of ischemic colitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muenster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nitra</city>
        <zip>950 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>L'hospitalet Del Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7281001&amp;StudyName=A%20Study%20To%20Investigate%20The%20Safety%20And%20Efficacy%20Properties%20Of%20PF-00547659%20In%20Patients%20With%20Active%20Ulcerative%20Colitis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <last_update_submitted>June 25, 2009</last_update_submitted>
  <last_update_submitted_qc>June 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

